Issues‎ > ‎Vol6n2‎ > ‎



Baraa Ramzi Abdulhameed*, Hazhar Ibrahim Karim*, Gulala Ibrahim Qader* and  Mohammed Omer Mohammed*

* Department of Pharmacology, College of Medicine, University of Sulaimani.

Submitted: 18/5/2016; Accepted: 18/10/2016/Published: 1/12/2016


The purpose of this study is to document the extent of pre and post-cholecystectomy retained bile duct stones in our region with evaluation of the endoscopic retrograde cholangio pancreatography role in their management.


Retrospective study.

Patients and Methods

This retrospective case series was carried out in Kurdistan center for gastroenterology and Hepatology in Sulaimani city–Iraq from January 2014 to January 2015. The records of 486 patients were retrospectively evaluated to collect demographic, clinical and procedure related data.


The mean age was 51 years (range14-88 years).The female : male ratio was 2.01:1 with females constituted 325 (66.87%) while males constituted 161 (33.12%).Less than quarter of the patients were referrals from Iraqi governorates other than Sulaimani governorate. The mean duration of the ERCP procedure was 27.5 min. Deep cannulation was successful in 452 (93.o1%) patients. There was 34 (6.99%) failure of cannulation. In cases that had successful cannulation a cholangiogram was obtained which showed bile duct dilatation. Endoscopic sphincterotomy is almost done in all cases before stone extraction, and it is an adjunct for stone removal which is done by basket or balloon. It was performed in 285 (84.2%) patients, followed by stone extraction in 341 (96.05%) patients, stenting in 208 (45.51%). The most common complications reported in this study were pancreatitis, bleeding and cholangitis. Elevated liver function tests and dilated CBD by ultrasound are the most accurate predictors of stones.


Despite its associated morbidity and risk of mortality, ERCP (Endoscopic Retrograde Cholangio Pancreatography) is an important method in managing pre and post cholecystectomy choledocholithiasis. Our indications, interventions and complications rates are comparable to those reported in other countries.


ERCP, KCGH, Sulaimani, endoscopic sphincterotomy, choledocholithiasis.


  1. Bailey CJ, Day C (1989) Traditional plant medicines as treatments for diabetes. Diabetes Care 12:553–564. 
  2. Budavari S, editor. The Merck Index. 13th ed. Whitehouse Station: Merck & Co Inc; 2001. p. 998. 
  3. Davidsen M B and Peters A L, Am J Med.,1997, 102, 99-110. 
  4. Inzucchi SI, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429–442 
  5. Kirpichnikov D, McFarlane S I and Sowers J R, Ann Intern Med.,2002, 137(1), 25-33. 
  6. DPP Research Group, N Engl J Med., 2002, 346, 393-403. 
  7. Pillay V. and Fassihi R. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. J Control Release. 1998; 55(1): 45-55. 
  8. Polli J. E. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. AAPS J. 2008; 10(2): 289-299. 
  9. Anderson N. H., Bauer M., et al. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. J Pharm Biomed Anal. 1998; 17(4-5): 811-822. 
  10. Arayne, M. et al. (2006). Development and validation of RP-HPLC method for analysis of metformin. Pak J Pharm Sci. 19 (1), p232. 
  11. Gadpe, H.H. and ParkishK.S.. (2011). Quantitative Determination and Validation of Metformin Hydrochloride in Pharmaceutical Using Quantitative Nuclear Magnetic Resonance Spectroscopy. E-Journal of Chemistry. 8 (2), 767. 
  12. Umapathi, P. et al. (2012). Quantitative Determination of Metformin Hydrochloride in Tablet Formulation Containing Croscarmellose Sodium as Disintegrant by HPLC and UV Spectrophotometry. TROP J PHARM RES. 11 (1), 107. 
  13. The United States Pharmacopeia 30: The National Formulary 25.2015 Rockville, the United States Pharmacopeial Convention, Inc,p433